期刊
CURRENT PHARMACEUTICAL DESIGN
卷 26, 期 31, 页码 3783-3798出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612826666200218104921
关键词
Castration-resistant prostate cancer; PSMA Theranostic; prostate biomarker; systems biology; network analysis; metabolic network; precision medicine; omics tool
Prostate cancer is the most prevalent type of cancer and the second cause of death in men worldwide. Various diagnostic and treatment procedures are available for this type of malignancy, but High-grade or locally advanced prostate cancers showed the potential to develop to lethal phase that can be causing dead. Therefore, new approaches are needed to prolong patients' survival and to improve their quality of life. Precision medicine is a novel emerging field that plays an essential role in identifying new sub-classifications of diseases and in providing guidance in treatment that is based on individual multi-omics data. Multi-omics approaches include the use of genomics, transcriptomics, proteomics, metabolomics, epigenomics and phenomics data to unravel the complexity of a disease-associated biological network, to predict prognostic biomarkers, and to identify new targeted drugs for individual cancer patients. We review the impact of multi-omics data in the framework of systems biology in the era of precision medicine, emphasising the combination of molecular imaging modalities with high-throughput techniques and the new treatments that target metabolic pathways involved in prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据